As prostate cancer progresses, it becomes increasingly aggressive and can metastasise. In this form, the tumor is difficult to treat, which is reflected in high mortality rates: Worldwide, the malignant disease of the prostate is the second most common cause of cancer death in men.
Diversity of Humira biosimilar launches reveals the difficulty of dethroning AbbVie’s megablockbuster
Sandoz, Boehringer Ingelheim, Samsung and others are now taking their shot at AbbVie’s megablockbuster Humira, with launches of their biosimilars on Saturday, and myriad approaches
July 4, 2023